Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 1839100 for cough in idiopathic or progressive pulmonary fibrosis
2023-510249-79-00Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Aug 2024
- Modality
- Small Molecules
- Countries
- 29
01
Overview
Phase 2, randomised, double-blind trial in idiopathic pulmonary fibrosis (IPF), pulmonary fibrosis (PF) and refractory chronic cough (RCC) comparing BI 1839100 with Placebo (2 arms). Primary endpoints: Change from baseline in 24-h cough frequency (IPF Phase IIa Week 4) and Change from baseline in 24-h cough frequency (IPF Phase IIa Week 12). Started Aug 2024; status: completed.
02
Drugs
BI 1839100
03
Conditions
idiopathic pulmonary fibrosis (IPF)pulmonary fibrosis (PF)refractory chronic cough (RCC)
Beyond the preview
Go deeper on 2023-510249-79-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-510249-79-00.